Tue, December 7, 2010
Mon, December 6, 2010
Fri, December 3, 2010
Thu, December 2, 2010
Wed, December 1, 2010
Tue, November 30, 2010
[ Tue, Nov 30th 2010 ] - Market Wire
2005 Certification
Mon, November 29, 2010
Thu, November 25, 2010
Wed, November 24, 2010
Tue, November 23, 2010
Mon, November 22, 2010
Sat, November 20, 2010
Fri, November 19, 2010
Thu, November 18, 2010
Wed, November 17, 2010
Tue, November 16, 2010
Mon, November 15, 2010
Sun, November 14, 2010
Fri, November 12, 2010
Thu, November 11, 2010
Wed, November 10, 2010

Salix Pharmaceuticals to Present at Piper Jaffray Conference


//health-fitness.news-articles.net/content/2010/ .. cals-to-present-at-piper-jaffray-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


RALEIGH, N.C.--([ BUSINESS WIRE ])--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the Piper Jaffray 22nd Annual Healthcare Conference in New York, NY on Tuesday, November 30 at 11:00 a.m. ET.

Interested parties can access a live audio web cast of the presentation at [ http://www.salix.com ]. A replay of the presentation will be available at the same location.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salixa™s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Companya™s gastroenterology specialty sales and marketing team.

Salix markets XIFAXAN® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets,), VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets, APRISOa" (mesalamine) extended-release capsules 0.375 g., METOZOLV® ODT (metoclopramide HCl), PEPCID® (famotidine) for Oral Suspension, Oral Suspension DIURIL® (Chlorothiazide), AZASAN® Azathioprine Tablets, USP, 75/100 mg, ANUSOL-HC® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Budesonide foam, crofelemer and rifaximin for additional indications are under development.

For full prescribing information, including BOXED WARNINGS for VISICOL, OSMOPREP and METOZOLV, on Salix products, please visit [ www.salix.com ] or contact the Company at 919 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol aSLXP.a

For more information please visit our web site at [ www.salix.com ]. Information on our web site is not incorporated in our SEC filings.


Publication Contributing Sources